Key Takeaways
- The Minnesota medical cannabis cancer study tracked 6,621 patients and showed significant symptom relief for cancer-related issues.
- Nearly 40% of patients reported relief from nausea and vomiting within four months of starting cannabis treatment.
- Patients also experienced improvements in anxiety and depression, with around 40% reporting meaningful reductions.
- Most side effects were mild, affecting only about 15% of patients, with dry mouth being the most common complaint.
- This study provides strong evidence for the benefits of medical cannabis in managing cancer symptoms, encouraging patients to consult healthcare providers.
Cancer treatment brings a long list of unwanted side effects, and patients have looked to medical cannabis for relief for years. Now, a new government-backed study gives that idea some real weight behind it.
The Minnesota Office of Cannabis Management (OCM) released findings on September 11th, from what officials describe as one of the largest studies ever involving medical cannabis treatment for cancer patients. Researchers tracked thousands of patients over eight years, and the results point to meaningful, if not universal, symptom relief.
For anyone following the medical cannabis space, this study adds real data to a conversation that’s often driven by anecdote. Lets take a look at what the numbers actually show.
What Did the Minnesota Cannabis and Cancer Study Find?
The OCM analyzed data from 6,621 patients enrolled in Minnesota’s medical cannabis program between July 1, 2015, and December 31, 2023. All patients had been certified as having cancer by their health care practitioner. Researchers drew on patient self-evaluations, enrollment records, cannabis purchase history, and symptom ratings collected at the time of each purchase.
Patients rated eight standard symptoms, including anxiety, depression, disturbed sleep, fatigue, nausea, pain, vomiting, and appetite loss, on a 0-10 scale both at enrollment and during follow-up visits. A drop of 30% or more in a symptom score counted as clinically meaningful improvement, a threshold backed by prior clinical research, particularly for pain.
At enrollment, the numbers show just how much these patients were struggling. Nearly 83% reported moderate to severe pain, 91.5% reported moderate to severe fatigue, and more than 70% reported moderate to severe anxiety and appetite loss. Against that backdrop, any measurable relief matters.
“These results show great promise in using cannabis for treating the symptoms that occur with cancer and cancer-related treatments,” said Dr. Grace Christensen, OCM senior research analyst, in the official press release. “Even minor relief can improve patients’ quality of life and help them better manage battling the disease.”
How Did Medical Cannabis Help With Nausea, Vomiting, and Appetite Loss?
These three symptoms are closely tied to both cancer itself and its treatment, and they showed some of the clearest improvement in the study.
Among patients with moderate to severe vomiting at enrollment, 47.2% saw at least a 30% reduction in symptom score within four months of their first medical cannabis purchase. Of those who improved and stayed in the program, 74.4% held onto that improvement for another four months. Overall, about a quarter of all patients both achieved and maintained relief from vomiting.
Nausea told a similar story. Nearly 40% of patients with moderate to severe nausea at enrollment saw meaningful improvement within four months, and 65.4% of those patients maintained it afterward.
Appetite loss followed the same pattern. Among patients with moderate to severe symptoms at the start, 38.2% reported improvement within four months, and 62.8% of those patients kept that improvement going for an additional four months.
Patients seemed to notice the difference themselves. As one participant put it in the report, cannabis provided “help with appetite, nausea, and peace of mind and motivation.” Another patient credited it with “lessening degree of pain, increase desire to eat.”
Did Medical Cannabis Reduce Anxiety, Depression, and Pain in Cancer Patients?
Mental health symptoms and physical pain showed improvement too, though the results varied by symptom.
Forty percent of patients with moderate to severe anxiety at enrollment reported improvement within four months, and nearly 65% of those maintained it. Depression scores improved for 43.6% of patients with moderate to severe symptoms, with 66.4% sustaining that improvement afterward. One caregiver noted the change directly: “Much less anxious and able to deal with things so much easier, it helps a lot with pain so I don’t have to take as much other stuff.”
Pain, the most commonly reported symptom in the study at 82.7% of patients, showed a smaller but still real effect. Nearly 30% of patients with moderate to severe pain saw at least a 30% score reduction within four months, and 53.1% of those patients maintained the improvement afterward. Overall, roughly 12% of all patients both achieved and sustained pain relief.
Dr. Dylan Zylla, oncologist and medical director of the HealthPartners Cancer Research Center, weighed in on the safety side of these findings. “Cannabis treatment appears relatively safe, and we now have strong observational evidence that many patients report better control of several cancer-related symptoms,” he said. “I recommend starting with a low dose of THC and adjusting up gradually every few days to reduce the risk of side effects.”
What Products Did Cancer Patients Use, and Were There Side Effects?
Purchasing data showed patients favored high-THC products across categories. Inhalation products, including flower and vape items, made up 48% of all purchases, while enteral products like capsules and gummies accounted for 42.5%. Among enteral products, 82.4% had a high or very high THC-to-CBD ratio.
Side effects were relatively uncommon and generally mild. Roughly 15% of patients reported an adverse side effect at some point during the study period. Of those reported effects, 60% were mild, 34% were moderate, and only 6.2% were classified as severe. Dry mouth was the single most common complaint, while fatigue topped the list of severe side effects.
It’s worth noting the study’s limitations. Researchers pointed to significant loss to follow-up, since a quarter of patients only made one purchase before leaving the program. That means the reported improvement rates are likely conservative, since the study can’t fully capture what happened to patients who stopped participating. The report also relied on observational data and self-evaluations rather than a placebo-controlled trial, so while the associations are strong, they don’t prove cannabis directly caused every improvement.
What Does This Mean for Minnesota’s Medical Cannabis Program?
Minnesota’s medical cannabis program now serves more than 90,000 registered patients who use cannabis for cancer, epilepsy, Alzheimer’s disease, and other qualifying conditions. That’s notable given a larger national trend: most states see enrollment drop once they legalize adult-use cannabis, but Minnesota has bucked that pattern with steady growth.
Part of that growth traces back to policy changes. The Minnesota Legislature eliminated patient fees in 2023 and expanded the list of qualifying conditions in 2024, and enrollment has doubled since those changes took effect.
OCM Executive Director Eric Taubel framed the study as part of a bigger commitment to data-driven policy. “These are encouraging results for people who are battling cancer,” Taubel said. “Governor Walz and the State Legislature have fought to expand access to Minnesota’s medical cannabis program while prioritizing the collection of data on its effectiveness at addressing and relieving the symptoms of the conditions and diseases patients are facing.”
That data-first approach sets Minnesota apart. Few states require this level of ongoing research into how medical cannabis programs actually perform for patients, which makes findings like these more valuable to the broader medical cannabis conversation nationally.
Should Cancer Patients Consider Medical Cannabis for Symptom Relief?
This study adds solid, government-backed evidence to a growing body of research supporting medical cannabis as a symptom management tool for cancer patients. The improvements in vomiting, nausea, appetite, anxiety, depression, and pain are real and measurable, and side effects were mostly mild.
That said, this isn’t a one-size-fits-all solution. Every patient’s cancer, treatment plan, and response to cannabis will differ. OCM recommends consulting with a medical professional before starting any medical cannabis regimen, and the agency’s Guide to Safer Cannabis Use in Minnesota offers a helpful starting point for patients weighing their options.
For patients and caregivers navigating a cancer diagnosis, this research offers something valuable: real numbers behind a treatment option many have already turned to. Read the full report for the complete breakdown of methodology and results.
Frequently Asked Questions
The study analyzed data from 6,621 patients enrolled in Minnesota’s medical cannabis program with a cancer-related qualifying condition between July 1, 2015, and December 31, 2023.
Within four months of starting medical cannabis, 39.9% of patients with moderate to severe nausea and 47.2% of patients with moderate to severe vomiting reported significant improvement.
Yes, but they were generally mild. About 15% of patients reported an adverse side effect, and 60% of those were classified as mild. Dry mouth was the most commonly reported side effect.
The study found that 29.9% of patients with moderate to severe pain saw at least a 30% reduction in pain scores within four months, and just over half of those patients maintained that relief for an additional four months.
Minnesota’s medical cannabis program has more than 90,000 registered patients using cannabis to manage symptoms from cancer, epilepsy, Alzheimer’s disease, and other qualifying conditions.
